MILAN, Italy — A Japanese trial of low-dose thrombolysis — alteplase (tPA 0.6mg/kg) — has shown neutral results in patients with an unknown time of acute stroke, a so-called "wake-up" stroke, who were ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Despite concerns ...

PURPOSE: To evaluate the safety and efficacy of alteplase (TPA) for restoring function to occluded central venous catheters (CVCs). PATIENTS AND METHODS: The study design was a phase III, open-label, ...

Twenty years ago stroke doctors celebrated the arrival of a powerful new weapon: the clot-clearing drug tPA. It was hailed as a lifesaver and has proved to be one for hundreds of thousands of patients ...

CHICAGO — Low-dose alteplase infused directly into the culprit artery early after coronary reperfusion does not reduce microvascular obstruction (MVO) in acute ST-segment elevation MI (STEMI), a ...

CHICAGO, IL—Low-dose coronary alteplase infused early after PCI does not reduce the likelihood of microvascular obstruction (MVO) in ST-segment elevation MI, the T-Time trial suggests. Colin Berry, MD ...

Please provide your email address to receive an email when new articles are posted on . In patients with moderate or severe ischemic stroke, a lower dose of IV tenecteplase yielded less favorable ...

A Johns Hopkins study has shown that patients treated for a type of stroke caused by bleeding in the brain, or intracerebral hemorrhage, survived more often if given 1 milligram instead of the ...

Please provide your email address to receive an email when new articles are posted on . At 90 days after minor nondisabling acute ischemic stroke, there was no difference in functional outcomes ...

HOLLYWOOD, FL—Even with lower-dose infusions given for short durations, patients with pulmonary embolism (PE) who receive ultrasound-enhanced catheter delivery of recombinant tissue plasminogen ...